Odyssey Therapeutics, Inc. (ODTX)

Company

Odyssey Therapeutics, Inc. (ODTX)

StatusMay 08, 2026
BiotechnologyBiotechnology
Initial Public Offering / IPOInitial Public Offering / IPO

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

IPO
Prospectus volume (424B4)279 m USD15,500,000 shares · 18 USD/share

Odyssey is a clinical-stage biopharmaceutical company led by a team and board of drug hunters seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. We believe our deep understanding of immunobiology, coupled with leading expertise in medicinal and computational chemistry, protein biochemistry, structural biology, genetics, and pharmacology, allows us to identify and drug key signaling nodes that drive disease. We have prioritized targets where we believe the underlying disease biology is understood through genetic, clinical, or translational evidence. 

Chart/Sentiment

Financials

Scroll to Top